WebAug 8, 2024 · Doxorubicin is a major substrate of cytochrome P450, CYP3A4, CYP2D6, and P-glycoprotein (Pgp). Several clinically significant interactions have been reported with other inhibitors of CYP3A4, CYP2D6, and/or Pgp that can increase doxorubicin concentration, resulting in more or worsening side effects and toxicity at lower levels … WebAvoid concurrent use of doxorubicin HCl with inhibitors and inducers of ... 7.1 Effect of CYP3A4 Inhibitors, Inducers and P-gp . 7.2 Trastuzumab 7.3 Paclitaxel . 7.4 Dexrazoxane 7.5 6-Mercaptopurine . 8 USE IN SPECIFIC POPULATIONS . 8.1 Pregnancy . 8.3 Nur. s. ing Mothers 8.4 Pediatric Use .
Effects of quercetin on the bioavailability of doxorubicin in rats ...
WebNov 16, 2024 · The known anticancer drugs included tyrosine kinase inhibitors (imatinib, sorafenib, dasatinib, gefitinib, nilotinib, erlotinib, and afatinib), PARP inhibitors (olaparib, rucaprib), CDK4/6 inhibitors … WebApr 1, 2024 · Doxorubicin is a chemotherapeutic drug used for the treatment of various malignancies; however, patients can experience cardiotoxic effects and this has limited … goals timeline examples
Frontiers Effect of CYP3A4 Inhibitors and Inducers on ...
WebJan 30, 2024 · In a zebrafish model of AIC, Asnani et al. demonstrated that doxorubicin treatment significantly increased levels of cytochrome P450 family 1 (CYP1) enzymes, and that various substances... WebJan 14, 2024 · Intracellular concentration of doxorubicin in target cancer cells is a major determinant of therapeutic success of doxorubicin-based regimens. As known, doxorubicin is a substrate of P-glycoprotein (P-gp), the drug efflux transporter in the ABC superfamily. High expression level of P-gp in cancer cells can prevent intracellular … WebNov 16, 2024 · In a randomized phase II clinical trial in patients diagnosed with small cell lung cancer receiving cyclophosphamide, doxorubicin, vincristine, and etoposide (CAVE), a daily dose of 480 mg was given in … bonds childrens clothing online